- Home
- Publications
- Publication Search
- Publication Details
Title
Metformin and cancer: new applications for an old drug
Authors
Keywords
-
Journal
MEDICAL ONCOLOGY
Volume 29, Issue 2, Pages 1314-1327
Publisher
Springer Nature
Online
2011-02-07
DOI
10.1007/s12032-011-9846-7
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- The antidiabetic drug metformin suppresses HER2 (erbB-2) oncoprotein overexpression via inhibition of the mTOR effector p70S6K1 in human breast carcinoma cells
- (2011) Alejandro Vazquez-Martin et al. CELL CYCLE
- Metformin inhibits breast cancer cell growth, colony formation and induces cell cycle arrest in vitro
- (2011) Irina N. Alimova et al. CELL CYCLE
- Metformin induces unique biological and molecular responses in triple negative breast cancer cells
- (2011) Bolin Liu et al. CELL CYCLE
- Obesity related hyperinsulinaemia and hyperglycaemia and cancer development
- (2011) Susen Becker et al. ARCHIVES OF PHYSIOLOGY AND BIOCHEMISTRY
- Diabetes and Cancer: A Consensus Report
- (2010) E. Giovannucci et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Metformin Prevents Tobacco Carcinogen-Induced Lung Tumorigenesis
- (2010) R. M. Memmott et al. Cancer Prevention Research
- Metformin Suppresses Colorectal Aberrant Crypt Foci in a Short-term Clinical Trial
- (2010) K. Hosono et al. Cancer Prevention Research
- Activation of AMPK is necessary for killing cancer cells and sparing cardiac cells
- (2010) Scott A. Shell et al. CELL CYCLE
- Genome-wide inhibitory impact of the AMPK activator metformin on [kinesins, tubulins, histones, aurorasandpolo-like kinases] M-phase cell cycle genes in human breast cancer cells
- (2010) Cristina Oliveras-Ferraros et al. CELL CYCLE
- Metformin against TGFβ-induced epithelial-to-mesenchymal transition (EMT): From cancer stem cells to aging-associated fibrosis
- (2010) Sílvia Cufí et al. CELL CYCLE
- Metformin regulates breast cancer stem cello ntogeny by transcriptional regulation of the epithelial-mesenchymal transition (EMT) status
- (2010) Alejandro Vazquez-Martin et al. CELL CYCLE
- Metformin, Independent of AMPK, Inhibits mTORC1 in a Rag GTPase-Dependent Manner
- (2010) Adem Kalender et al. Cell Metabolism
- The antidiabetic drug metformin: a pharmaceutical AMPK activator to overcome breast cancer resistance to HER2 inhibitors while decreasing risk of cardiomyopathy
- (2009) A. Vazquez-Martin et al. ANNALS OF ONCOLOGY
- Metformin inhibits inflammatory angiogenesis in a murine sponge model
- (2009) D.O. Xavier et al. BIOMEDICINE & PHARMACOTHERAPY
- Chemical Genomics Identifies the Unfolded Protein Response as a Target for Selective Cancer Cell Killing during Glucose Deprivation
- (2009) S. Saito et al. CANCER RESEARCH
- Metformin Selectively Targets Cancer Stem Cells, and Acts Together with Chemotherapy to Block Tumor Growth and Prolong Remission
- (2009) H. A. Hirsch et al. CANCER RESEARCH
- Insulin glargine use and short-term incidence of malignancies—a population-based follow-up study in Sweden
- (2009) J. M. Jonasson et al. DIABETOLOGIA
- Serum Insulin, Glucose, Indices of Insulin Resistance, and Risk of Prostate Cancer
- (2009) Demetrius Albanes et al. JNCI-Journal of the National Cancer Institute
- Enhancing CD8 T-cell memory by modulating fatty acid metabolism
- (2009) Erika L. Pearce et al. NATURE
- The Epithelial-Mesenchymal Transition Generates Cells with Properties of Stem Cells
- (2008) Sendurai A. Mani et al. CELL
- Insulin, Insulin-Like Growth Factor-I, and Risk of Breast Cancer in Postmenopausal Women
- (2008) M. J. Gunter et al. JNCI-Journal of the National Cancer Institute
- AMPK Phosphorylation of Raptor Mediates a Metabolic Checkpoint
- (2008) Dana M. Gwinn et al. MOLECULAR CELL
- The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level
- (2008) I Ben Sahra et al. ONCOGENE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More